Chris Evert reveals third cancer diagnosis amid ongoing health battle
Yahoo Sports • 1 min read • Latest: Jun 27, 2026, 11:30 AM
Last updated Jun 27, 2026
Chris Evert announced in June 2026 that her ovarian cancer has returned for a third time. The three-time Wimbledon champion initially faced cancer in 2021 and has undergone multiple surgeries and rounds of chemotherapy since then. Following her diagnosis, Evert emphasized the importance of genetic testing and early detection, particularly after losing her sister to ovarian cancer. She shared that despite the challenges, she remains optimistic and dedicated to fighting the disease. Evert looks forward to continuing to raise awareness through her experiences.
- •Evert's third cancer diagnosis was disclosed in June 2026.
- •She first diagnosed with stage 1 ovarian cancer in 2021.
- •Evert underwent a hysterectomy and chemotherapy as part of her treatment.
- •Her story highlights the importance of genetic testing for cancer risk.
- •She remains optimistic and is advocating for cancer awareness.
- 11:30 AMYahoo Sports — Chris Evert Is Facing Cancer for a Third Time. Inside the Tennis Star's 5-Year Journey with the 'Relentless' Disease
"Three-time Wimbledon champion Chris Evert has been diagnosed with cancer three times since 2021
Sources
External linksOriginal reporting and copyright belong to the linked sources. SportsNewsReport.com aggregates and links — it does not republish full articles.
Related Stories
Last 14 days
ATP•Sep 6, 2026, 12:33 PMFallout continues after Venus, Serena skip last night’s US Open postmatch press conference
ATP•Sep 6, 2026, 11:45 AMAfter Brutal Day At U.S. Open, 10 Americans Still Remain
ATP•Sep 6, 2026, 10:07 AMFive US Open Round of 16 matches Sunday worth planning your day around
ATP•Sep 6, 2026, 10:06 AMAmerican players in US Open: Coco Gauff, Ben Shelton still alive
ATP•Sep 6, 2026, 10:06 AMUS Open scores today: Day 8 schedule, results, Day 9 matchups, how to watch- ATP•Sep 6, 2026, 9:16 AMU.S. Open recap Day 6: Taylor Townsend backs up 2025 run after challenging 12 months
